EpilepsyGTx Partners with ClearPoint Neuro for Precision Delivery of Gene Therapy EPY201 in Focal Refractory Epilepsy Trial
核心洞察
EpilepsyGTx (搜索) and ClearPoint Neuro (搜索) announced a partnership to support targeted delivery of gene therapy candidate EPY201 for focal refractory epilepsy (搜索) (FRE).
The collaboration will use ClearPoint's MRI-guided SmartFlow Cannula and Neuro Navigation system to achieve sub-millimetric accuracy in administering EPY201 directly to the seizure focus.
EPY201 is designed as a single, minimally invasive gene therapy that reduces neuronal hyperexcitability locally without requiring resection or ablation of brain tissue.
EpilepsyGTx (搜索), a biotechnology company focused on gene therapies for refractory epilepsy, and ClearPoint Neuro (搜索), a global therapy-enabling company specializing in precise navigation and delivery to the brain, announced on July 14, 2026, a partnership to support the targeted delivery of EpilepsyGTx's lead gene therapy candidate, EPY201, for focal refractory epilepsy (搜索) (FRE). The collaboration will leverage ClearPoint's MRI-guided stereotactic navigation and delivery platform in the upcoming first-in-human Phase 1/2a clinical trial.
Under the agreement, EpilepsyGTx (搜索) will use the ClearPoint SmartFlow Cannula and the ClearPoint Neuro (搜索) Navigation system to administer EPY201. ClearPoint's platform is designed to support sub-millimetric accuracy for delivery to defined targets in the brain, enabling intraprocedural visualization of delivery to the intended seizure focus. The ClearPoint Navigation System is currently installed in over 100 active clinical sites globally for the delivery of gene and cell therapies to the central nervous system within the scope of preclinical studies, approved clinical trials, and commercial procedures.
The Unmet Need in Focal Refractory Epilepsy (搜索)
Focal epilepsy describes a group of disorders in which seizures arise from a specific part of the brain. When seizures persist following trials of at least two tolerated and appropriately chosen antiseizure medications, epilepsy is deemed refractory, or pharmacoresistant. FRE affects approximately 10 million patients worldwide, including two million patients in the US, UK, and EU. Current treatment options for these patients remain limited, often involving surgical resection or ablation of brain tissue.
EPY201: A Targeted Gene Therapy Approach
EPY201 is designed to be delivered directly into the seizure focus, with the aim of reducing neuronal hyperexcitability locally while limiting exposure beyond the target region in the brain. If successful, this approach will offer patients a single, minimally invasive option that does not require resection or ablation of brain tissue. The precision of delivery to the seizure focus is central to the therapeutic potential of EPY201.
Executive Perspectives
Nicolas Koebel, Chief Executive Officer of EpilepsyGTx (搜索), emphasized the importance of accurate delivery: "Accurate delivery to the seizure focus is central to the potential of EPY201 in FRE. ClearPoint's guided navigation system provides the precision and intraprocedural visualization we need as we prepare to evaluate EPY201 in first-in-human trials. We look forward to working with ClearPoint to support safe, targeted administration of EPY201 for people living with focal refractory epilepsy (搜索)."
Jeremy Stigall, Chief Business Officer & General Manager of Biologics and Drug Delivery at ClearPoint Neuro (搜索), stated: "EpilepsyGTx (搜索) is developing a targeted gene therapy approach for focal refractory epilepsy (搜索), a devastating condition affecting millions of patients. We are pleased to partner with them as the team advances this important program into clinical evaluation."
Clinical Development Path
The partnership directly supports the initiation of the first-in-human Phase 1/2a clinical trial evaluating EPY201 in patients with focal refractory epilepsy (搜索). The trial will utilize ClearPoint's guided navigation system to ensure precise, intraprocedurally visualized delivery of the gene therapy to the seizure focus, a critical factor for both the safety and efficacy of the investigational treatment.